Overview

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

Status:
Not yet recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

Phase:

Phase 3

Details

Lead Sponsor:

Anthos Therapeutics, Inc.

Collaborators:

IQVIA Biotech
Itreas

Treatments:

Dalteparin
Heparin, Low-Molecular-Weight
Tinzaparin